Catalyst Wire Dossier Catalyst Wire Dossier

Sacubitril/valsartan (Entresto)

sacubitril/valsartan · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Sacubitril/valsartan (Entresto), covering 2025-08-03 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction

See pricing